Can a sleep drug boost metabolic health in menopausal women?

NCT ID NCT05593653

Completed Symptom relief Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the sleep medication suvorexant (Belsomra) can reduce insomnia severity and improve metabolic health in midlife women who have both insomnia and signs of metabolic syndrome. Thirty-one healthy women aged 40-65 who were perimenopausal or postmenopausal took either suvorexant or a placebo for 4 weeks. Researchers measured changes in insomnia scores and fasting glucose levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Suvorexant (Belsomra)
What this could lead to: If it works, this could point toward a treatment that eases insomnia and improves metabolic health in midlife women.
What could go wrong: This is a small, completed Phase 4 trial with only 31 participants, so results may not apply widely. The drug may not significantly improve metabolic outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSOMNIA MENOPAUSE METABOLIC HEALTH

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.